The Technical Analyst
Dicerna Pharmaceuticals [DRNA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Dicerna Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $38.22
America/New_York / 31 des 1970 @ 19:00
| RATING 2022-02-09 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/20 | 3/20 | 4/20 | 1/21 | 2/21 | 3/21 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 37.23 - 39.21 ( +/- 2.59%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-12-28 | Koppel Adam | Sell | 3 080 237 | Common Stock |
| 2021-12-28 | Koppel Adam | Sell | 3 333 | Restricted Stock Units |
| 2021-12-28 | Koppel Adam | Sell | 25 000 | Director Stock Option (Right to Buy) |
| 2021-12-28 | Koppel Adam | Sell | 25 000 | Director Stock Option (Right to Buy) |
| 2021-12-28 | Koppel Adam | Sell | 25 000 | Director Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 0.00 |
| Last 100 transactions |
| Buy: 12 087 | Sell: 8 528 928 |
Forecast:
01:40 - $34.85
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $38.22 (0.00% ) |
| Volume | 5.54 mill |
| Avg. Vol. | 3.03 mill |
| % of Avg. Vol | 182.74 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For DRNA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
DRNA
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.
Latest Press Releases
2021-12-28 09:04:00 - Press Release
Novo Nordisk Announces Completion Of Dicerna Pharmaceuticals Acquisition
Lexington, mass.--(business wire)--novo nordisk today announced that the acquisition of dicerna, announced on 18 november 2021, has been completed.
2021-12-25 08:00:00 - Press Release
Dicerna Announces Expiration Of Hart-scott-rodino Act Waiting Period For Novo Nordisk Tender Offer To Acquire Dicerna
Lexington, mass.--(business wire)--dicerna announces expiration of hart-scott-rodino act waiting period for novo nordisk tender offer to acquire dicerna
2021-11-22 16:38:00 - Press Release
Shareholder Alert: Monteverde & Associates Pc Announces An Investigation Of Dicerna Pharmaceuticals, Inc. - Drna
New york, nov. 22, 2021 /prnewswire/ -- juan monteverde , founder and managing partner at monteverde & associates pc, a national securities firm rated top 50 in the 2018-2020 iss securities class action services report and headquartered at the empire state building in new york city, is investigating dicerna pharmaceuticals, inc. ("drna" or the "company") (drna) relating to its proposed acquisition by novo nordisk. under the terms of the agreement, drna shareholders will receive $38.25 in cash per share they own.
2021-11-18 20:58:00 - Press Release
Shareholder Alert: Weisslaw Llp Investigates Dicerna Pharmaceuticals, Inc.
New york, nov. 18, 2021 /prnewswire/ -- weisslaw llp is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of dicerna pharmaceuticals, inc. ("dicerna" or the "company") (nasdaq: drna) in connection with the proposed acquisition of the company by novo nordisk. under the terms of the merger agreement, the company's shareholders will receive $38.25 per share in cash for each share of dicerna common stock that they hold.
2021-11-18 14:45:00 - Press Release
Shareholder Alert: Levi & Korsinsky, Llp Notifies Investors Of An Investigation Into The Fairness Of The Sale Of Dicerna Pharmaceuticals, Inc. To Novo Nordisk
New york, new york--(newsfile corp. - november 18, 2021) - the following statement is being issued by levi & korsinsky, llp:to: all persons or entities who purchased dicerna pharmaceuticals, inc. ("dicerna" or the "company") (nasdaq: drna) stock prior to november 18, 2021.you are hereby notified that levi & korsinsky, llp has commenced an investigation into the fairness of the sale of dicerna to novo nordisk ("novo). under the terms of th
Latest News
2021-11-22 17:48:38 - GuruFocus
Shares of RNAi Drug Companies Pop After Novo Lays Out $3.3 Billion for Dicerna
Novo Nordisk AS ( NVO , Financial) is shelling out $3.3 billion to buy partner Dicerna Pharmaceuticals Inc. ( DRNA , Financial). That's $38.25 per share in cash, an 80% premium to the $21.28 closing price of Dicerna on Wednesday, Nov. 17, and the third-highest premium in a deal for a publicly-traded biotech this year, according to BioPharma Dive's database.
2021-11-19 11:30:12 - Zacks Investment Research
Novo Nordisk (NVO) Set to Acquire Dicerna for $3.3 Billion
Novo Nordisk (NVO) inks agreement to acquire Dicerna for $3.3 billion. The company is looking to boost its RNAi research platform with this acquisition.
2021-11-18 13:56:53 - Invezz
Dicerna Pharmaceuticals acquired by Novo Nordisk; Shares rocket 80%
Dicerna Pharmaceuticals (Nasdaq: DRNA) is a biopharma company that concentrates on developing RNAi therapeutics that announced that Novo Nordisk would acquire it for a total equity value of about $3.3 billion, shares in cash of $38.25 each. Both the Board of Directors of Novo Nordisk and Dicerna Pharmaceuticals unanimously approved this transaction.
2021-11-18 11:38:18 - The Motley Fool
Why Dicerna Pharmaceuticals Stock Is Rocketing Higher Today
A juicy buyout offer from Novo Nordisk is giving Dicerna shareholders a big reason to cheer.
2021-11-18 11:01:39 - InvestorPlace
LCID, RIVN, FSR: Why Are EV Stocks Down Today?
We're taking a look at why EV stocks are down today and there are a couple of reasons shares of investors' favorites are falling. The post LCID, RIVN, FSR: Why Are EV Stocks Down Today?
2021-11-18 10:29:25 - InvestorPlace
DRNA Stock: The $3B Novo Nordisk Deal That Has Dicerna Pharma Shares Skyrocketing Today
Dicerna Pharmaceuticals (DRNA) stock is surging higher on Thursday following news of a massive $3.3 billion deal with Novo Nordisk. The post DRNA Stock: The $3B Novo Nordisk Deal That Has Dicerna Pharma Shares Skyrocketing Today appeared first on InvestorPlace.
2021-11-18 09:28:16 - Benzinga
Novo Nordisk Swallows Dicerna In $3.3B Buyout: All You Need To Know
Novo Nordisk A/S (NYSE: NVO) has agreed to acquire Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) for $38.25 per share in cash, representing a total equity value of $3.3 billion and a premium of 80% to Dicerna's closing price on November 17, 2021. "The acquisition of Dicerna accelerates Novo Nordisk's research within RNAi and expands the usage of the RNAi technology," said Marcus Schindler, the CSO of Novo Nordisk.
2021-11-18 08:54:51 - Pulse2
Why Novo Nordisk (NVO) Is Buying Dicerna Pharmaceuticals (DRNA) For $3.3 Billion
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) announced it entered into a definitive agreement with Novo Nordisk A/S (NYSE: NVO) under which Novo Nordisk will acquire Dicerna. This is why.
2021-11-18 07:17:13 - Market Watch
Novo Nordisk strikes $3.3 billion to buy research partner Dicerna Pharmaceuticals
Novo Nordisk NVO, +0.37% NOVO.B, +0.69% said it's buying Dicerna Pharmaceuticals DRNA, -0.09% for $3.3 billion, or $38.25 per share in cash. Dicerna ended Wednesday at $21.28.
2021-11-09 14:54:05 - Seeking Alpha
Dicerna Pharmaceuticals, Inc. (DRNA) CEO Doug Fambrough on Q3 2021 Results - Earnings Call Transcript
Dicerna Pharmaceuticals, Inc. (DRNA) CEO Doug Fambrough on Q3 2021 Results - Earnings Call Transcript